![]() |
Name |
deoxyleporin B
|
Molecular Formula | C22H25NO2 | |
IUPAC Name* |
10-methyl-4-phenyl-6-prop-1-enyl-2,6,6a,7,8,9,10,10a-octahydroisochromeno[4,3-c]pyridin-1-one
|
|
SMILES |
CC=CC1Oc2c(-c3ccccc3)c[nH]c(=O)c2C2C(C)CCCC12
|
|
InChI |
InChI=1S/C22H25NO2/c1-3-8-18-16-12-7-9-14(2)19(16)20-21(25-18)17(13-23-22(20)24)15-10-5-4-6-11-15/h3-6,8,10-11,13-14,16,18-19H,7,9,12H2,1-2H3,(H,23,24)/b8-3+/t14-,16+,18+,19+/m1/s1
|
|
InChIKey |
ZBTREMSWPKVXFU-XOUBBZGBSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 335.45 | ALogp: | 4.9 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 42.1 | Aromatic Rings: | 4 |
Heavy Atoms: | 25 | QED Weighted: | 0.759 |
Caco-2 Permeability: | -4.848 | MDCK Permeability: | 0.00001160 |
Pgp-inhibitor: | 0.108 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.178 | Plasma Protein Binding (PPB): | 98.43% |
Volume Distribution (VD): | 0.676 | Fu: | 1.21% |
CYP1A2-inhibitor: | 0.565 | CYP1A2-substrate: | 0.755 |
CYP2C19-inhibitor: | 0.897 | CYP2C19-substrate: | 0.41 |
CYP2C9-inhibitor: | 0.861 | CYP2C9-substrate: | 0.943 |
CYP2D6-inhibitor: | 0.415 | CYP2D6-substrate: | 0.512 |
CYP3A4-inhibitor: | 0.824 | CYP3A4-substrate: | 0.361 |
Clearance (CL): | 4.369 | Half-life (T1/2): | 0.085 |
hERG Blockers: | 0.118 | Human Hepatotoxicity (H-HT): | 0.092 |
Drug-inuced Liver Injury (DILI): | 0.829 | AMES Toxicity: | 0.373 |
Rat Oral Acute Toxicity: | 0.37 | Maximum Recommended Daily Dose: | 0.873 |
Skin Sensitization: | 0.037 | Carcinogencity: | 0.052 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.362 |